Competitive pressure and procedure mix shift
Open vascular products compete with endovascular devices and larger rivals with broader resources.
- Scope
- Core vascular surgery portfolio
- Materiality
- high
LeMaitre Vascular, Inc
LeMaitre Vascular Inc. develops, manufactures, and sells specialized vascular devices and human tissue cryopreservation services used mainly in open vascular surgery and dialysis access. Built through a long series of acquisitions and internal development, the company has assembled a portfolio of branded products for treating peripheral vascular disease, end-stage renal disease, and related cardiovascular conditions.
31,4 %
71,5 %
23,1 %
+13,5 %
12.89
12.89
| % | |
|---|---|
| Biologic vascular products | 53% Bovine, ovine, human tissue, and other biologic patches and grafts used in vascular and cardiac repair. |
| Synthetic and biosynthetic grafts | 17% Polyester, ePTFE, polycarbonate, and hybrid graft products used in vascular reconstruction. |
| Surgical instruments and access devices | 20% Valvulotomes, embolectomy catheters, shunts, closure systems, and related open-surgery tools. |
| Specialty imaging and procedure tools | 5% Angioscopes, contrast injectors, and other adjunct devices used during vascular procedures. |
| Human tissue cryopreservation services | 5% RestoreFlow processing, preservation, and cryopreservation services for human vascular and cardiac tissue. |
The core customer is the vascular surgeon, who buys LeMaitre products for open vascular surgery and dialysis access...
- Vascular surgeonsprimary
Primary call point buying valvulotomes, grafts, catheters, and patches for peripheral vascular disease and dialysis access.
- Hospitals and clinicsprimary
End customers and care settings that purchase the devices and services for surgical use, often via direct sales or consignment.
- Cardiac surgeonssecondary
Buy biologic patches and cryopreservation-related products such as RestoreFlow and CardioCel for cardiac applications.
- Distributorssecondary
Purchase in markets without direct sales coverage and resell into hospitals and clinics.
- Other surgical specialtiesemerging
General surgeons and neurosurgeons buy selected niche products where the portfolio fits their procedures.
LeMaitre sells globally, with principal markets in the United States, Europe, Canada, and Asia Pacific...
- •United States is the largest market and home to headquarters and most manufacturing
- •Europe is a major sales region with headquarters in Germany and multiple local offices
- •Asia Pacific is served from Singapore with offices across Japan, China, Korea, Australia, and Thailand
- •Canada has a North American sales office in Vaughan, supporting regional coverage
- •About 43% of 2025 sales were outside the United States, increasing FX exposure
LeMaitre’s strategy is to deepen its focus on niche vascular products, expand direct sales coverage, and add...
01
Acquire complementary vascular productsmedium-term
Acquisitions have been a primary growth engine and broaden the portfolio without relying on one product.
02
Expand direct sales internationallyshort-term
Direct coverage supports pricing, surgeon relationships, and market penetration in new countries.
03
Grow biologic and adjacent-call-point productsmedium-term
Biologic offerings are a large share of sales and can extend the company beyond the core vascular surgeon base.
The business depends on a narrow set of specialized medical procedures, so competitive pressure, reimbursement changes,...
Acquisition execution risk
A meaningful part of growth has come from acquisitions, which may be harder to source or integrate.
- Scope
- Portfolio expansion strategy
- Materiality
- high
Supply and donor tissue constraints
Biologic and cryopreservation products rely on limited-source suppliers and tissue availability.
- Scope
- RestoreFlow and biologic grafts
- Materiality
- high
Regulatory and product liability exposure
Medical devices and human tissue services face FDA, foreign regulatory, and liability risk.
- Scope
- All product lines and processing services
- Materiality
- high
Foreign exchange volatility
A large share of sales is outside the U.S. and denominated in foreign currencies.
- Scope
- Europe and Asia Pacific sales
- Materiality
- medium
Revenue recognition and returns reserve
Can shift quarterly revenue and gross margin
Contingent consideration from acquisitions
Can create operating income volatility
Inventory and deferred cost estimates
Affects cost of sales and asset carrying values
Foreign currency translation
Affects reported revenue and operating results
: 28.4.2026